Financial comparisons Guard Therapeutics International AB
Equities
GUARD
SE0021181559
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.60 SEK | +2.07% | +2.78% | -17.32% |
08-29 | First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER | CI |
08-27 | Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study | MT |
Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
---|---|---|---|---|---|---|---|
7.92B | +9.74% | +13.98% | +6.52% | +3.82% | 0.46x | ||
14.98B | +9.06% | +20.36% | +32.01% | +5.22% | 3.45x | ||
1.83B | -24.08% | -15.43% | - | -11.94% | 0.17x | ||
1.64B | +24.61% | +29.93% | +5.07% | +4.31% | 1.46x | ||
6.85B | -68.84% | -61.90% | -28.59% | -21.29% | 2.38x | ||
8.12B | +7.54% | +19.31% | +6.90% | +3.58% | 2x | ||
2.33B | +42.31% | +50.91% | +18.27% | +14.91% | -1.85x | ||
1.16B | +14.50% | +31.94% | +14.11% | +6.29% | 0.4x | ||
1.89B | +15.00% | +17.94% | +59.83% | +18.80% | -0.29x | ||
1.97B | +17.37% | +26.90% | +4.69% | +2.75% | 0.69x | ||
4.13B | +11.49% | +20.31% | +16.70% | +6.95% | 2.34x | ||
532M | -40.26% | - | - | - | - | ||
11.58M | -3,768.28% | -4,207.12% | -34.76% | -30.38% | 3.85x | ||
681M | +19.38% | +22.41% | +9.00% | - | -1.79x | ||
788M | -46.45% | -44.80% | -76.34% | -13.26% | 3.21x | ||
249M | -203.30% | -194.99% | -157.13% | - | 0.99x | ||
1.04B | +27.44% | +35.35% | +9.95% | +7.09% | -1.51x | ||
1.63B | +13.88% | +14.92% | +13.86% | +6.82% | 1.36x | ||
Average | 3.21B | -218.83% | -248.23% | -6.24% | +0.25% | 1.02x | |
Weighted average by Cap. | 5.44B | -92.28% | -96.58% | +4.21% | +0.09% | 1.26x |
- Stock Market
- Equities
- GUARD Stock
- Sector Guard Therapeutics International AB
- Financial comparisons
MarketScreener is also available in this country: United States.
Switch edition